Paper Review Records
全部论文审稿周期
20 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
56
天
Upfront venetoclax plus quizartinib with low-dose cytarabine or azacitidine in older unfit patients with acute myeloid leukemia: the phase I/II VEN-A-QUI trial
作者
Juan Miguel Bergua; Pilar Lloret-Madrid; Rebeca Rodríguez-Veiga; Isabel Cano-Ferri; Ferran Vall-llovera; Antonio García-Guiñón; Joaquín Gómez-Espuch; Mercedes Colorado; Ignacio Casas-Avilés; Jordi Esteve; Antonia Sampol; María V. Verdugo; Ágata Almela; Marta Valero; Evelyn Acuña-Cruz; Blanca Boluda; Laura Torres; Joaquín Martínez-López; Eva Barragán; Teresa Cedena; Rosa Ayala; Beatriz Martín-Herreros; Bruno Paiva; David Martínez-Cuadrón; Pau Montesinos展开收起
作者单位
1. Hospital San Pedro de Alcántara, Cáceres, Spain; 2. Hospital Universitari i Politécnic La Fe, Valencia, Spain; 3. Hospital Universitari Mútua Terrassa, Barcelona, Spain; 4. Hospital Arnau de Vilanova, Lleida, Spain; 5. Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain; 6. Hospital Universitario Marqués de Valdecilla, Santander, Spain; 7. Hospital Clínic de Barcelona, Barcelona, Spain; 8. Son Espases University Hospital, IdISBa, Palma, Spain; 9. Hospital de Jerez, Jerez de la Frontera, Cádiz, Spain; 10. Hospital Clínico de León, León, Spain; 11. Hospital Arnau de Vilanova, València, Spain; 12. Hospital 12 de Octubre, Universidad imas12, Complutense University, CNIO, Madrid, Spain; 13. Cancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada, Universidad de Navarra (CIMA), IDISNA, CIBER-ONC CB16/12/00369, Pamplona, Spain展开收起
69
天
Successful treatment of systemic light chain amyloidosis with a novel high-avidity BCMA CAR
作者
Kiavasch Mohammad Nejad Farid; Ute Hegenbart; Brigitte Neuber; Angela Hückelhoven-Krauss; Marc S. Raab; Carsten Müller-Tidow; Peter Dreger; Stefan Schönland; Anita Schmitt; Uta Elisabeth Höpken; Armin Rehm; Michael Schmitt展开收起
作者单位
1. Medical Faculty University of Heidelberg and Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; 2. Department of Microenvironmental Regulation in Autoimmunity and Cancer, Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany; 3. Department of Translational Tumorimmunology, Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany展开收起
119
天
Adjuvant capecitabine-based oral chemotherapy plus trastuzumab as adjuvant therapy in patients with HER2-positive, node-negative breast tumors measuring 1 cm or smaller (ORCHID study)
作者
Min He; Lei Fan; Yi-Feng Hou; Guang-Yu Liu; Xiu-Zhi Zhu; Li Chen; Yin Liu; Wen-Jia Zuo; Gen-Hong Di; Can-Ming Chen; Zhen Hu; Jun-Jie Li; Kun-Yu Zhang; Li-Chen Tang; Jiong Wu; Yi-Zhou Jiang; Ke-Da Yu; Zhong-Hua Wang; Zhi-Ming Shao展开收起
作者单位
1. Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Shanghai, China; 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China展开收起
84
天
A phase Ia first-in-human study of BPB-101, a novel trifunctional antibody targeting the GARP/TGF-β complex and PD-L1, in patients with locally advanced or metastatic solid tumors
作者
Yuxiang Ma; Yufeng Guo; Shuang Deng; Haitao Lan; Suxia Luo; Keqiang Zhang; Qingqing Hu; Tao Fu; Pengxiang Wu; Qiuyue Cao; Luyang Zhao; Li Mao; Lieming Ding; Yan Huang; Yuanyuan Zhao; Yang Zhang; Jinhui Xue; Li Zhang; Hongyun Zhao展开收起
作者单位
1. Department of Clinical Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Centre, Guangdong Provincial Clinical Research Centre for Cancer, Guangzhou, China; 2. Department of Oncology, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, China; 3. Phase I Clinical Research Center, Henan Cancer Hospital, Zhengzhou, China; 4. Department Five of Gynecological Oncology, Hunan Cancer Hospital, Changsha, China; 5. Betta Pharmaceuticals Co., Ltd, Hangzhou, China; 6. Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Centre, Guangdong Provincial Clinical Research Centre for Cancer, Guangzhou, China展开收起
69
天
Futibatinib as a bridge to transplantation and post-transplant maintenance in blast-phase MLN- ZMYM2::FGFR1
作者
Tino Vollmer; Christoph Schell; Milena Pantic; Dietmar Pfeifer; Robert Zeiser; Khalid Shoumariyeh展开收起
作者单位
1. Department of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; 2. Institute of Surgical Pathology, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany展开收起
165
天
Exploring the potential of vamotinib in Ph+ leukemias: is it indeed a 3rd generation tyrosine kinase-inhibitor?
作者
Chantal Lucini; Isabella Sponseiler; Anna-Maria Bandian; Julia Senkiv; Thomas Lion展开收起
作者单位
1. St. Anna Children’s Cancer Research Institute (CCRI), Vienna, Austria; 2. Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria; 3. Department of Pediatrics, Medical University of Vienna, Vienna, Austria; 4. St. Anna Children´s Cancer Research Institute, Vienna, Austria展开收起
FAQ
Journal of Hematology & Oncology审稿要多久?
截至2026-11-18,CrushSCI 收录了 Journal of Hematology & Oncology 的 20 篇完整审稿记录。最快一篇从收稿到录用用了 47 天(The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026,2026-06-04 收稿,2026-07-21 录用),最慢一篇用了 165 天;平均 79.7 天,中位数 71.5 天。
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。
